Raman Bahal Selected Research

pHLIP protein

1/2022	Targeted Suppression of miRNA-33 Using pHLIP Improves Atherosclerosis Regression.
1/2020	Ku80-Targeted pH-Sensitive Peptide-PNA Conjugates Are Tumor Selective and Sensitize Cancer Cells to Ionizing Radiation.
1/2020	Tumor-Targeted, Cytoplasmic Delivery of Large, Polar Molecules Using a pH-Low Insertion Peptide.
12/2019	Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Raman Bahal Research Topics

Disease

11	Neoplasms (Cancer) 01/2022 - 02/2013
3	Lymphoma (Lymphomas) 11/2021 - 02/2015
2	Drug-Related Side Effects and Adverse Reactions 01/2022 - 01/2022
2	Myotonic Dystrophy (Dystrophia Myotonica) 01/2018 - 01/2018
2	Splenomegaly 01/2018 - 10/2016
2	Inborn Genetic Diseases (Disease, Hereditary) 10/2016 - 04/2015
1	Atherosclerotic Plaque (Atheroma) 01/2022
1	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 01/2022
1	Atherosclerosis 01/2022
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2022
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022
1	Obesity 01/2022
1	Leukemia 11/2021
1	Rare Diseases (Rare Disease) 01/2021
1	Ischemic Stroke 01/2021
1	Hypercholesterolemia 01/2021
1	Stroke (Strokes) 01/2021
1	Carcinogenesis 12/2019
1	Kidney Diseases (Kidney Disease) 11/2019
1	Brain Neoplasms (Brain Tumor) 01/2019
1	Glioma (Gliomas) 01/2019
1	Glioblastoma (Glioblastoma Multiforme) 01/2019
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2018
1	Thalassemia 01/2018
1	Reticulocytosis 10/2016
1	Cystic Fibrosis (Mucoviscidosis) 04/2015
1	Squamous Cell Carcinoma of Head and Neck 02/2013
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2013

Drug/Important Bio-Agent (IBA)

7	MicroRNAs (MicroRNA)IBA 01/2022 - 02/2015
7	Peptide Nucleic AcidsIBA 11/2021 - 02/2013
4	pHLIP proteinIBA 01/2022 - 12/2019
4	Pharmaceutical PreparationsIBA 01/2022 - 02/2015
4	Peptides (Polypeptides)IBA 01/2020 - 02/2015
2	OligonucleotidesIBA 01/2022 - 01/2021
2	Antisense OligonucleotidesIBA 01/2022 - 01/2022
2	Nucleic AcidsIBA 01/2020 - 01/2018
2	RNA (Ribonucleic Acid)IBA 01/2018 - 01/2018
2	GlobinsIBA 01/2018 - 10/2016
2	Guanidine (Guanidine Nitrate)FDA Link 10/2013 - 02/2013
1	AntigensIBA 01/2022
1	Immunoconjugates (Immunoconjugate)IBA 01/2022
1	CollagenIBA 01/2022
1	casimersenIBA 01/2022
1	LipidsIBA 01/2022
1	Biological ProductsIBA 01/2022
1	polyhistidineIBA 09/2021
1	Paclitaxel (Taxol)FDA LinkGeneric 09/2021
1	ALN-PCSIBA 01/2021
1	AntagomirsIBA 01/2021
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2021
1	Radiation-Sensitizing AgentsIBA 01/2020
1	Indicators and Reagents (Reagents)IBA 01/2020
1	DNA (Deoxyribonucleic Acid)IBA 01/2020
1	Fatty Acids (Saturated Fatty Acids)IBA 11/2019
1	Hemoglobins (Hemoglobin)IBA 01/2018
1	Nucleic Acid ProbesIBA 01/2018
1	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 04/2015
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2013
1	CateninsIBA 10/2013
1	LuciferasesIBA 10/2013
1	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 10/2013
1	NucleotidesIBA 02/2013
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 02/2013
1	ErbB Receptors (EGF Receptor)IBA 02/2013
1	Cetuximab (Erbitux)FDA Link 02/2013
1	glutarylphenylalanine-4-nitroanilideIBA 02/2013

Therapy/Procedure

9	Therapeutics 11/2021 - 02/2015
1	Precision Medicine 11/2021
1	Radiotherapy 01/2020
1	Drug Therapy (Chemotherapy) 01/2019
1	Intravenous Administration 10/2016